Hypertension in Pregnancy: Chronic and Gestational HTN Guide
Clinical Practice Update — Classification, Antihypertensive Selection, and Postpartum Care
This is an original clinical education article informed by current guidelines and evidence. See References below for source documents.
- Clinical Focus
- Evidence-based approach to chronic and gestational hypertension in pregnancy, from preconception through postpartum follow-up
- Target Audience
- Obstetricians, family physicians, maternal-fetal medicine specialists, internists, nurse midwives
- Setting
- Preconception counselling, prenatal care, labor and delivery units, postpartum clinics
- Source Evidence
- •ACOG Practice Bulletin — Chronic Hypertension in Pregnancy (reaffirmed with CHAP update, 2022)
- •ISSHP Classification and Diagnosis of Hypertensive Disorders of Pregnancy (2018)
- •NICE NG133 — Hypertension in Pregnancy: Diagnosis and Management (2019)
- •CHAP Trial — Treatment for Mild Chronic Hypertension During Pregnancy (NEJM, 2022)
- •CHIPS Trial — Less-Tight vs Tight BP Control in Pregnancy (NEJM, 2015)
Key Clinical Takeaways
Effective management of hypertension in pregnancy begins with classification: is this chronic, gestational, or preeclampsia? The 2022 CHAP trial redefined treatment thresholds for chronic disease, and modern drug selection is narrower but clearer than a decade ago. The points below distill the evidence into actionable rules for prenatal and postpartum care.
- 1Offer preconception counselling to every woman with chronic hypertension — the time to optimise BP, switch unsafe medications, and establish baseline organ function is before conception → Preconception
- 2Classify hypertension in pregnancy by timing: before 20 weeks (chronic), after 20 weeks without proteinuria (gestational), or with proteinuria or end-organ involvement (preeclampsia) → Classification
- 3Treat chronic hypertension to a target below 140/90 mmHg, following the CHAP trial — tighter control reduced adverse pregnancy outcomes without increasing small-for-gestational-age births → BP Targets
- 4Choose labetalol, extended-release nifedipine, or methyldopa as first-line oral antihypertensives — each has the safety record required for use throughout pregnancy → Drug Selection
- 5Do not use ACE inhibitors, angiotensin-receptor blockers, renin inhibitors, or mineralocorticoid-receptor antagonists in pregnancy — all are fetotoxic → Drug Selection
- 6Start low-dose aspirin 81–162 mg nightly from 12–16 weeks in every woman with chronic hypertension to reduce the risk of superimposed preeclampsia → Prevention
- 7Deliver gestational hypertension at 37+0 weeks and uncomplicated chronic hypertension at 38+0 to 39+6 weeks — both earlier if superimposed preeclampsia develops → Delivery Timing
- 8Continue antihypertensive therapy postpartum and counsel every patient about lifelong cardiovascular risk — hypertension in pregnancy is a sentinel event for future chronic disease → Postpartum
- 9Monitor chronic hypertension patients monthly for superimposed preeclampsia with BP, urine protein screening, and serial growth scans → Monitoring
Classifying Hypertension in Pregnancy
The foundation of managing hypertension in pregnancy is accurate classification. Timing (before or after 20 weeks) and the presence of proteinuria or end-organ involvement separate four distinct entities that share a BP threshold of ≥140/90 mmHg but require very different pathways of care.
Diagnose chronic hypertension when BP is ≥140/90 mmHg before pregnancy, before 20 weeks of gestation, or persisting beyond 12 weeks postpartum. If a woman presents for care after 20 weeks without prior records, treat as chronic hypertension if BP does not normalise by 12 weeks postpartum — but monitor carefully for preeclampsia in the interim.
Strong Rec High Evidence ACOG 2022 ISSHP 2018Diagnose gestational hypertension when a previously normotensive woman develops BP ≥140/90 after 20 weeks, without proteinuria or end-organ dysfunction. Reclassify as preeclampsia if proteinuria or organ involvement subsequently appears — this occurs in roughly one in four women initially labelled gestational.
Strong Rec High Evidence ACOG 2020Measure BP correctly in pregnancy: seated, after at least 5 minutes of rest, arm supported at heart level, appropriate cuff size (large cuff if mid-upper arm circumference exceeds 33 cm). Confirm an elevated reading with a second measurement at least 15 minutes later on the same visit, and a third reading on a separate day for non-severe-range values.
Strong Rec Moderate Evidence NICE 2019 AHA 2023Distinguishing the Four Entities at a Glance
| Condition | Timing of Onset | Proteinuria / Organ Involvement | Resolution After Delivery | Key Clinical Clue |
|---|---|---|---|---|
| Chronic hypertension | Preexisting or before 20 weeks | Absent unless superimposed | Persists (by definition) | Documented pre-pregnancy BP or first-trimester readings |
| Gestational hypertension | After 20 weeks, new onset | Absent | By 12 weeks postpartum | Normal urine dipstick, normal platelets, normal LFTs |
| Preeclampsia | After 20 weeks (rarely postpartum) | Present (one or the other) | Usually by 6 weeks postpartum | Headache, visual symptoms, RUQ pain, abnormal labs |
| Superimposed preeclampsia | Worsening after 20 weeks on a background of chronic HTN | New-onset or worsening proteinuria, or new organ involvement | Chronic HTN persists; preeclampsia features resolve | Sudden BP jump, rising proteinuria, or new thrombocytopenia |
Preconception and Early Pregnancy Management
The best outcomes in hypertension in pregnancy begin before conception. Optimising control, switching unsafe drugs, and establishing baseline renal and cardiac function simplify every subsequent decision.
Switch ACE inhibitors, ARBs, renin inhibitors, and mineralocorticoid-receptor antagonists to pregnancy-safe alternatives before conception, or at the first missed period if conception was unplanned. Brief first-trimester exposure likely poses less risk than previously feared, but ongoing use in the second and third trimesters causes fetopathy.
Strong Rec High Evidence ACOG 2022 FDAObtain baseline labs in every woman with chronic hypertension entering pregnancy: urine protein quantification (24-hour collection or protein:creatinine ratio), serum creatinine, electrolytes, fasting glucose, and lipid panel. An electrocardiogram is reasonable; echocardiography is indicated when duration exceeds 5 years, in poorly controlled disease, or with cardiac symptoms.
Strong Rec Moderate Evidence ACOG 2022Prescribe low-dose aspirin 81–162 mg taken nightly beginning at 12–16 weeks of gestation (and continuing until delivery) in every woman with chronic hypertension. Chronic hypertension is itself a high-risk factor that triggers aspirin prophylaxis.
Strong Rec High Evidence USPSTF 2021 ACOG 2020Counsel about risks specific to chronic hypertension in pregnancy: superimposed preeclampsia (risk 17–25%), fetal growth restriction, preterm delivery, placental abruption, and cesarean section. Risks rise sharply with BP above 160/110 or pre-existing end-organ damage.
Strong Rec Moderate Evidence ACOG 2022- Review all antihypertensive, anticoagulant, and lipid-lowering medications; switch fetotoxic agents
- Confirm BP consistently <140/90 before conception whenever possible
- Check renal function (creatinine, urine protein), fasting glucose, HbA1c, lipid panel
- Perform baseline ECG; echocardiography if duration >5 years or concerning symptoms
- Screen for secondary causes if early-onset or resistant hypertension
- Counsel about aspirin prophylaxis starting 12–16 weeks
- Discuss prognosis, risks, and realistic expectations for the pregnancy
Antihypertensive Drug Selection for Hypertension in Pregnancy
Three agents form the backbone of ongoing oral therapy for hypertension in pregnancy: labetalol, extended-release nifedipine, and methyldopa. Others have roles in specific scenarios or acute emergencies, but these three cover the vast majority of long-term management decisions.
Prescribe labetalol 100–400 mg two or three times daily (max 2.4 g/day) as the preferred first-line agent for sustained BP control in pregnancy. It has the broadest safety evidence and can be used acutely (IV) or chronically (oral).
Strong Rec High Evidence ACOG 2022 NICE 2019Prescribe extended-release nifedipine 30–90 mg once daily (max 120 mg/day) as an equally valid first-line option — particularly useful in women with asthma, bradycardia, or labetalol intolerance.
Strong Rec High Evidence ACOG 2022 CHAP Trial 2022Consider methyldopa 250–500 mg three or four times daily (max 3 g/day) as an alternative first-line agent, particularly in women already stabilised on it before pregnancy. Its antihypertensive effect is modest but its long safety record in pregnancy is unmatched.
Moderate Rec Moderate Evidence ACOG 2022 NICE 2019Do not use ACE inhibitors, angiotensin-receptor blockers, direct renin inhibitors, or mineralocorticoid-receptor antagonists at any stage of pregnancy. Fetopathy includes oligohydramnios, renal dysgenesis, pulmonary hypoplasia, skeletal deformities, and neonatal death.
Against High Evidence FDA ACOG 2022Avoid atenolol because of its association with fetal growth restriction when used for extended periods in early pregnancy. If a beta-blocker is needed, prefer labetalol.
Against Moderate Evidence ACOG 2022Target BP below 140/90 mmHg in chronic hypertension during pregnancy, following the CHAP trial. Treat severe-range hypertension (≥160/110) urgently regardless of aetiology.
Strong Rec High Evidence CHAP Trial 2022 ACOG 2022Oral Antihypertensives: A Practical Comparison
| Drug | Starting Dose | Max Daily | Breastfeeding Safety | Practical Tips |
|---|---|---|---|---|
| Labetalol | 100 mg BID | 2.4 g (split TID) | Compatible — minimal milk transfer | Avoid in asthma, heart block, sinus bradycardia |
| Nifedipine ER | 30 mg daily | 120 mg | Compatible | Avoid short-acting IR for chronic use — causes BP spikes |
| Methyldopa | 250 mg BID–TID | 3 g (split 3–4x) | Compatible | Sedation, depression; rare hepatitis & positive Coombs test |
| Hydralazine (oral) | 10 mg QID | 200 mg | Compatible | Second-line; reflex tachycardia, SLE-like reaction at higher doses |
| Thiazide diuretics | HCTZ 12.5 mg daily | 25 mg | Caution — may reduce milk supply | May continue if established pre-pregnancy; avoid initiating de novo |
| ACE inhibitors & ARBs | Contraindicated antepartum | — | Enalapril and captopril acceptable postpartum | Fetotoxic — switch before conception |
Managing Gestational Hypertension
Gestational hypertension is often considered the “quieter” form of hypertension in pregnancy — but it carries real risks. Up to 25% of women initially diagnosed with gestational hypertension progress to preeclampsia, and the condition itself is associated with preterm birth, fetal growth restriction, and placental abruption.
Admit all women with newly diagnosed gestational hypertension for initial evaluation: confirm BP, exclude preeclampsia with urine protein and CBC, platelets, transaminases, and creatinine. Outpatient management is acceptable afterwards if all parameters are reassuring and surveillance is reliable.
Strong Rec Moderate Evidence ACOG 2020Screen for progression to preeclampsia at every visit: BP, symptoms (headache, visual changes, epigastric pain), and urine protein. If BP becomes severe (≥160/110) or proteinuria or organ involvement appears, reclassify immediately and escalate management.
Strong Rec High Evidence ACOG 2020 NICE 2019Treat gestational hypertension with antihypertensive medication when BP is persistently ≥140/90 mmHg — the same threshold that now applies to chronic hypertension post-CHAP. Target 130–139 / 80–89 mmHg.
Moderate Rec Moderate Evidence NICE 2019 ISSHP 2018Deliver gestational hypertension at 37+0 weeks if BP is controlled and no preeclampsia features have emerged. Expectant management beyond this point does not improve neonatal outcomes.
Strong Rec High Evidence ACOG 2020 HYPITAT TrialRecognising Superimposed Preeclampsia
Superimposed preeclampsia is the most feared complication of chronic hypertension in pregnancy, affecting roughly one in five women with underlying disease. It is also the most under-recognised — the baseline elevation in BP obscures the sudden worsening that would raise alarm in an otherwise healthy woman.
- A sudden, sustained rise in BP requiring uptitration of previously stable medication
- New-onset proteinuria (protein:creatinine ratio ≥0.3, or dipstick 2+) after 20 weeks in a woman previously without proteinuria
- A significant worsening of pre-existing proteinuria
- Thrombocytopenia (<100,000/µL) where counts were previously normal
- Transaminases twice the upper limit of normal
- Rising creatinine or a doubling of baseline creatinine
- New headache, visual disturbances, or right upper quadrant pain
- Pulmonary edema
Monitor monthly for superimposed preeclampsia: BP (ideally including home readings), urine dipstick at every prenatal visit, and a baseline protein:creatinine ratio early in pregnancy for comparison. Check CBC, platelets, creatinine, and transaminases each trimester — more often when concern arises.
Strong Rec Moderate Evidence ACOG 2022Perform serial fetal growth ultrasounds every 4 weeks starting at 28 weeks in women with chronic hypertension. Fetal growth restriction is a leading complication and may precede the maternal features of superimposed preeclampsia.
Strong Rec Moderate Evidence ACOG 2022 SMFM 2021Deliver uncomplicated chronic hypertension at 38+0 to 39+6 weeks. Deliver at 37+0 weeks if antihypertensive therapy is needed; deliver at 34+0 weeks or earlier if superimposed preeclampsia with severe features develops.
Strong Rec Moderate Evidence ACOG 2022 SMFM 2019Clinical Decision Pathway
A question-based approach to hypertension in pregnancy at the first elevated reading. Work through each question before prescribing.
Postpartum Care and Long-Term Follow-Up
The postpartum period is the most neglected phase of hypertension in pregnancy care. Blood pressure often worsens in the first 5 to 7 days after delivery as mobilised fluid returns to the intravascular space, and new-onset postpartum preeclampsia remains possible for at least 6 weeks.
Continue inpatient BP monitoring for at least 72 hours after delivery in any woman with antepartum hypertension. Check BP at 7–10 days after discharge — sooner if symptomatic or if home readings exceed 150/100 mmHg.
Strong Rec Moderate Evidence ACOG 2020 NICE 2019Continue antihypertensives postpartum in women who needed them antepartum. Labetalol, nifedipine, and enalapril are all compatible with breastfeeding — the first two typically continued from pregnancy, enalapril often added postpartum for women returning to prior ACE inhibitor therapy.
Strong Rec Moderate Evidence ACOG 2020 LactMedAvoid NSAIDs (including ibuprofen and ketorolac) for postpartum analgesia in women with persistent hypertension or renal impairment — they can worsen BP and reduce renal perfusion. Acetaminophen and short courses of opioids are preferred alternatives.
Conditional Rec Moderate Evidence ACOG 2020Counsel every woman with hypertension in pregnancy about her future cardiovascular risk. A history of gestational hypertension or preeclampsia approximately doubles the lifetime risk of chronic hypertension, coronary disease, stroke, and heart failure. Chronic hypertension that predates pregnancy compounds this risk.
Strong Rec High Evidence AHA 2021 ACOG 2020Postpartum Follow-Up Timeline
| Time Point | What to Do | Red Flags | Common Pitfalls |
|---|---|---|---|
| 0–72 hours | Inpatient BP q4h; symptom review q shift; continue magnesium 24h if indicated | BP ≥160/110, headache, visual changes, RUQ pain | Dismissing BP spike as “pain-related” without treating |
| 3–10 days | Home BP twice daily; outpatient review at 7–10 days; provide cuff | Home BP ≥150/100, any severe symptom | Assuming “the baby is out, risk is over” |
| 2 weeks | Review BP trend; adjust meds; assess for postpartum preeclampsia risk | Persistent severe HTN needing multiple agents | Early weaning of medications before BP truly stable |
| 6 weeks | Reassess BP; if normal, begin slow medication taper; basic labs | Persistent BP elevation or proteinuria beyond 12 weeks | Not reclassifying persistent HTN as chronic |
| 3–6 months | Cardiovascular risk assessment; lipid panel; weight, BMI; lifestyle counselling | Metabolic syndrome features, diabetes | Lost to follow-up after 6-week visit |
| Annual (lifelong) | BP check, CV risk reassessment, diabetes screening | Recurrent BP elevation | Missing the obstetric history in primary care records |
Evidence in Context
What the evidence shows, where the major trials changed practice, and where genuine uncertainty remains in managing hypertension in pregnancy.
The CHAP Trial: Why BP Targets Changed
Before 2022, US practice tolerated BP up to roughly 160/105 in chronic hypertension before initiating treatment, out of concern that lowering BP might reduce placental perfusion and cause small-for-gestational-age infants. The CHAP trial randomised over 2,400 women with mild chronic hypertension to treatment (target <140/90) versus no treatment unless BP became severe.
Treatment reduced a composite primary outcome of preeclampsia with severe features, medically indicated preterm birth before 35 weeks, placental abruption, or fetal or neonatal death, with no increase in small-for-gestational-age births.
ACOG revised its guidance in 2022 to recommend treating chronic hypertension to <140/90, closely aligning with long-standing NICE and ISSHP practice.
The CHIPS Trial: Tight vs Less-Tight Control
The 2015 CHIPS trial compared tight (target diastolic 85) versus less-tight (target diastolic 100) BP control in women with chronic or gestational hypertension. The primary composite outcome of pregnancy loss or high-level neonatal care did not differ between groups, but severe hypertension was more common in the less-tight group. This result foreshadowed the CHAP findings and supported tighter control even before CHAP confirmed maternal benefit.
Where ACOG, ISSHP, and NICE Agree
All three frameworks now align on a <140/90 BP target in chronic hypertension, the preferred use of labetalol, nifedipine, and methyldopa, the contraindication of ACE inhibitors and ARBs in pregnancy, and aspirin prophylaxis for chronic hypertension. They also agree on 37-week delivery for gestational hypertension and flexible late-term delivery for uncomplicated chronic hypertension.
Where Practice Still Varies
Whether to pharmacologically treat gestational hypertension (as opposed to chronic) at the same <140/90 threshold remains less certain. NICE supports treatment; ACOG still considers pharmacologic therapy for non-severe gestational hypertension optional. Extrapolation from CHAP would support treatment, but dedicated trial data are limited.
The role of home BP monitoring in routine antenatal care, the use of angiogenic biomarkers, and optimal postpartum BP targets all remain areas of evolving practice.
Long-Term Cardiovascular Risk
Large cohort studies have consistently shown that women with a history of hypertension in pregnancy have a two- to four-fold increased risk of future cardiovascular disease. Hypertension often reappears within 5–10 years. The American Heart Association now recognises adverse pregnancy outcomes — including hypertensive disorders — as sex-specific risk enhancers for atherosclerotic cardiovascular disease, justifying earlier and more aggressive primary prevention.
References
- 1.Tita AT, Szychowski JM, Boggess K, et al. Treatment for Mild Chronic Hypertension during Pregnancy (CHAP). N Engl J Med. 2022;386(19):1781–1792. doi:10.1056/NEJMoa2201295
- 2.Magee LA, von Dadelszen P, Rey E, et al. Less-Tight versus Tight Control of Hypertension in Pregnancy (CHIPS). N Engl J Med. 2015;372(5):407–417. doi:10.1056/NEJMoa1404595
- 3.American College of Obstetricians and Gynecologists. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin No. 222. Obstet Gynecol. 2020;135(6):e237–e260. doi:10.1097/AOG.0000000000003891
- 4.Brown MA, Magee LA, Kenny LC, et al. Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice. Hypertension. 2018;72(1):24–43. doi:10.1161/HYPERTENSIONAHA.117.10803
- 5.National Institute for Health and Care Excellence. Hypertension in Pregnancy: Diagnosis and Management. NICE Guideline NG133. 2019. nice.org.uk/guidance/ng133
- 6.US Preventive Services Task Force. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality. JAMA. 2021;326(12):1186–1191. doi:10.1001/jama.2021.14781
- 7.Parikh NI, Gonzalez JM, Anderson CAM, et al. Adverse Pregnancy Outcomes and Cardiovascular Disease Risk: AHA Scientific Statement. Circulation. 2021;143(18):e902–e916. doi:10.1161/CIR.0000000000000961
How to Read the Evidence Tags
Every recommendation carries two tags — one for recommendation strength and one for evidence quality — along with a source tag. These are Medaptly’s own simplified interpretations designed for bedside readability.
Recommendation Strength
| Tag | What It Means |
|---|---|
| Strong Rec | High-quality evidence broadly supports this action. |
| Moderate Rec | The weight of evidence favours this action. |
| Conditional Rec | The benefit is less certain — individualise. |
| Against | Evidence shows no benefit or potential harm. |
Evidence Quality
| Tag | What It Means |
|---|---|
| High Evidence | Multiple well-designed RCTs or high-quality meta-analyses. |
| Moderate Evidence | Single RCT or large observational studies. |
| Low Evidence | Expert consensus or small studies. |